Valuation: Alvotech

Market Cap 1.82B 1.58B 1.49B 1.35B 2.54B 175B 2.55B 17.8B 6.88B 88.57B 6.84B 6.69B 282B P/E 2026 *
98.1x
P/E 2027 * 17.2x
Enterprise Value 2.9B 2.51B 2.37B 2.15B 4.04B 278B 4.06B 28.33B 10.95B 141B 10.88B 10.64B 449B EV / Sales 2026 *
4.39x
EV / Sales 2027 * 3.71x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.59%
1 week-2.11%
Current month-1.73%
1 month+25.77%
3 months+31.78%
6 months+41.27%
Current year-0.58%
1 week 4.9
Extreme 4.9
5.53
1 month 3.75
Extreme 3.75
5.53
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Executive Officer

117,271 0.0355%
1/4/26 Sell

Founder

318,000 0.0963%
1/4/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%-2.11%-35.93%-44.20% 1.82B
+0.76%+1.20%-0.81%+27.60% 45.91B
-0.32%+4.61%+43.90%+26.98% 44.25B
-4.36%-5.66%+338.30%+516.88% 41.99B
+0.46%-0.83%+6.38%+73.76% 39.58B
-0.17%-3.22%+10.29%+38.69% 31.08B
-0.65%+5.14%+25.61%+120.17% 17.21B
+3.30%-5.03% - - 16.27B
+2.06%+7.50%+21.44%+38.57% 14.96B
+0.86%+9.05%+0.47%-33.54% 13.42B
Average +0.47%+0.80%+45.52%+84.99% 26.65B
Weighted average by Cap. -0.04%+0.29%+69.48%+121.50%

Financials

2026 *2027 *
Net sales 659M 571M 540M 490M 919M 63.25B 924M 6.45B 2.49B 32.08B 2.48B 2.42B 102B 776M 672M 635M 577M 1.08B 74.41B 1.09B 7.58B 2.93B 37.74B 2.91B 2.85B 120B
Net income 30.36M 26.31M 24.87M 22.58M 42.31M 2.91B 42.57M 297M 115M 1.48B 114M 112M 4.71B 109M 94.55M 89.37M 81.13M 152M 10.47B 153M 1.07B 412M 5.31B 410M 401M 16.92B
Net Debt 1.08B 933M 882M 801M 1.5B 103B 1.51B 10.53B 4.07B 52.4B 4.05B 3.96B 167B 1.06B 916M 866M 786M 1.47B 101B 1.48B 10.34B 3.99B 51.44B 3.97B 3.88B 164B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
16/09/26 US$5.100 +1.59% 3,867,633
15/09/26 US$5.020 -0.59% 610,025
14/09/26 US$5.050 -4.54% 674,194
11/09/26 US$5.290 +0.95% 667,872
10/09/26 US$5.240 +0.58% 540,857
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.100USD
Average target price
6.800USD
Spread / Average Target
+33.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!